A world-first clinical trial conducted at the Royal Adelaide Hospital (RAH) and at hospitals across Australia and New Zealand has identified the best fluid treatment to reduce the risk of patients requiring dialysis after a kidney transplant.
Around one in three people who receive a kidney transplant suffer delayed graft function, which means the transplant doesn’t work immediately and they require dialysis.
To reduce the risk of this occurring, patients are given up to eight litres of IV fluid in the first two days after a kidney transplant.
The BEST Fluids trial compared the use of two intravenous (IV) fluids, Plasma-Lyte 148 and saline, finding Plasma-Lyte 148 reduces the need for dialysis by 25 per cent.
Australian Health Journal spoke with the lead-author of the study, RAH Nephrologist and University of Adelaide researcher, Dr Michael Collins.
Dr Collins provided background by stating, “While both types of fluids have been used during kidney transplantation in recent years, until now there had been little robust evidence to demonstrate which one was the most effective and safest to use.”
During the four-year study, these fluids were trialled in 808 patients with kidney failure, who received a kidney transplant from a deceased organ donor at the RAH and 15 other hospitals in Australia and New Zealand.
Saline is the most common type of IV fluid and contains salt (sodium chloride) and water and has been the standard treatment in kidney transplantation. Plasmalyte 148 is a balanced crystalloid fluid containing a mixture of salts, which more closely resembles what is in human blood.
Researchers at the University of Adelaide and University of Sydney, working with the Australasian Kidney Trials Network team and the ANZDATA Registry at the South Australian Health and Medical Research Institute (SAHMRI), found 30 per cent of participants who received Plasma-Lyte 148 needed dialysis after transplant, compared with 40 per cent of participants who received saline.
Commenting on the findings and potential impact to clinical care, Dr Collins said, “Our finding of a substantial reduction in dialysis with balanced crystalloid compared with saline, without any increase in complications or side effects, provides a strong justification to change clinical practice.”
Using Plasma-Lyte 148 did not result in more complications or side effects compared to saline. At one year after the transplant, both groups had similar levels of kidney function while rates of death, rejection and loss of kidney transplant function were also similar for both groups.
The results of the study are now being used to improve the health of kidney transplant patients in Australia and New Zealand and it is likely that practice will change at transplant units around the world.
Dr Collins added, “Balanced fluids are relatively cheap and widely available, so we hope this practise can now be used for most of the estimated 200,000 kidney transplant operations conducted across the globe each year.”
The BEST Fluids trial was funded by the National Health and Medical Research Council (NHMRC) administered Medical Research Future Fund (MRFF) Australia, the Health Research Council of New Zealand, and the Royal Australasian College of Physicians, with trial fluids supplied by Baxter Australia and New Zealand. The results of the study have been published in The Lancet.
You Might also like
-
Jack Lancaster, Evolution Surgical
Continuing the Australian Health Journal, People In Health Care series is Jack Lancaster, the CEO of Evolution Surgical, an Australian owned company established in 2014, specialising in spinal fusion implants and custom instrumentation.
Jack talks about how the company works closely with surgeons to design custom solutions manufactured to surgical requirements, and ultimately, to the benefit of the Australia patient.
-
Victorian social prescribing program underway
n Part 2 of the Models of Care on Social Prescribing, Australian Health Journal spoke to 4 people involved in the Connect Local program under the Connecting Communities to Care 4 year program. The free program for over 65’s promotes wellbeing through social connection and is underway in the Glen Eira community in Melbourne.
– Deidre McGill, Executive General Manager, At Home Support, Bolton Clarke
– Ann Van Leerdam, Connect Local Community Connector, Bolton Clarke
– Dr Rajna Ogrin, Senior Research Fellow, Bolton Clarke Research Institute, Bolton Clarke - Dr Daniel Fineberg, Deputy Director General Medicine, Alfred Hospital, Victoria -
Misinformation impacts routine vaccines
More significant changes in recent years have been health-related misinformation eroding trust in healthcare professionals, leading to people seeking alternative treatments or avoiding medical advice altogether. This can make it more difficult for healthcare professionals to provide effective treatment and care.
Recent vaccines delivered as part of the COVID-19 response, are having a consequential impact on the uptake of routine vaccines.
Australian Health Journal spoke with Dr Paul Griffin, an Infectious Diseases Physician and Microbiologist at Mater Health, and who has been involved in over 150 clinical trials in the field of infectious disease.
Paul talks about the importance of having reputable sources of information that can used to encourage people to understand what is involved in clinical trials and the roles of vaccines.